Emisphere Receives Notice Of Results From Novartis For Oral PTH. Print E-mail
By Staff and Wire Reports   
Friday, 17 June 2011 19:05
Below is a look at some of the headlines for companies that made news in the healthcare sector on June 17, 2011.

Novartis AG (NYSE:NVS) informed Emisphere Technologies, Inc. (OTC:EMIS) of the results of its recently completed Proof of Concept study for an oral PTH1-34 using Eligen in post-menopausal women with osteoporosis or osteopenia, Emisphere's technology.

Novartis informed Emisphere that, although the study confirmed that oral PTH1-34 was both safe and well-tolerated, several clinical endpoints were not met. Novartis has terminated the study and anticipates no further work on the oral formulation of PTH1-34.


Also Friday:


ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP)
, a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, announced that its MuGard partner in China, RHEI Pharmaceuticals has received the acceptance letter from the State Food and Drug Administration (SFDA) of China acknowledging all necessary documentation for the MuGard has been submitted and accepted.  

Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today the results from its Special Meeting of Shareholders held on Friday, June 17, 2011.

ERT (NASDAQ:ERT), announced today that Keith Schneck, the Company's Chief Financial Officer, is scheduled to present at the 2011 Wells Fargo Securities Healthcare Conference at 1:30 PM ET on Thursday, June 23, 2011 in Boston.

Esterline Corporation (NYSE: ESL), a leading specialty manufacturer serving the aerospace and defense markets, today announced that it has selected L-3 Communications executive Michel Potvin to serve as Platform President of the company's four, U.S.-based control systems operations.

Kendle International Inc. (Nasdaq:KNDL) ("Kendle"), announced today that it has increased the consideration amount offered for its cash tender offer and consent solicitation for any and all of its $142.5 million aggregate principal amount of outstanding 3.375% Convertible Senior Notes due 2012 (CUSIP No. 48880LAA5; ISIN No. US48880LAA52) (the "Notes").

K-V Pharmaceutical Company (NYSE:  KVa/KVb) announced today that it has entered into a definitive agreement to divest Nesher Pharmaceuticals, Inc., its generics subsidiary, and the Company's generic business and assets to Zydus Pharmaceuticals (USA), Inc. for approximately $60 million in cash.

NuVim, Inc. (PINKSHEETS: NUVM), a leading provider of nutritional refrigerated ready to drink beverages and powder mixes, announced today they will begin a Wal-Mart Roll Back promotion in the Florida Wal-Mart Supercenters.

Regenicin, Inc. (OTCBB: RGIN), a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs, recently repaid short-term secured loans totaling $242,993.54.

Regeneron Pharmaceuticals, Inc. (Nasdaq:REGN) announced that NASDAQ has halted trading of the company's common stock today.

Sunshine Biopharma, Inc. (OTCBB: SBFM) a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has executed an agreement with The Jewish General Hospital, one of McGill University's Hospital Centers, to conduct the necessary research and development to advance Sunshine's lead compound, Adva-27a, through the various stages of preclinical studies and Phase I clinical trials.

Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and active pharmaceutical ingredients (API) today discussed the non-cash, non-operational financial impact from the warrants issued in January 2008 under the ASC 815-40-15 (formerly EITF 07-05).

VIVUS, Inc. (Nasdaq:VVUS) today announced that the positive results from REVIVE-RP (TA-303), a phase 3 clinical trial evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED),will be presented this afternoon at the 2011 Cancer Survivorship and Sexual Health Symposium in Washington D.C.  

Watson Pharmaceuticals, Inc. (NYSE:WPI) today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for Nabumetone Tablets USP, 500 mg and 750 mg. Watson expects to launch the product shortly.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter